Prevencio Granted U.S. Patent for Highly Accurate, Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease
24 Julio 2024 - 8:07AM
Business Wire
Prevencio, Inc., a leader in AI-powered blood tests for
cardiovascular diagnostics, announces that the United States Patent
and Trademark Office has issued a patent for its highly accurate
blood test, HART CADhs, which assesses a patient’s risk of
obstructive coronary artery disease, also referred to as
obstructive heart disease. The company utilized its Artificial
Intelligence (AI)-driven HART platform and expertise in cardiac
blood tests to develop HART CADhs.
“Prevencio is pleased with the advancement of our patent
portfolio, which is crucial for maintaining our competitive
advantage,” said Rhonda Rhyne, President and Chief Executive
Officer of Prevencio. “This is the fourth patent issued for our
novel AI-driven, multiple protein blood tests. We have several more
patents pending.”
In research conducted with Massachusetts General Hospital, HART
CADhs demonstrated an 86% AUC accuracy, outperforming
standard-of-care tests such as exercise, echocardiography and
nuclear stress tests which collectively had an accuracy of 52%
AUC.
Cardiovascular disease is the leading cause of death in the U.S.
and globally. According to the American Heart Association (AHA),
the U.S. spends approximately $318 billion annually on
cardiovascular disease and stroke, or approximately 10% of the $3.2
trillion spent on total healthcare. By 2030, AHA projects that 45%
of the U.S. adult population will have cardiovascular disease, with
healthcare-related expenditures exceeding $1 trillion.
Rhyne added, “Given the cost, complexity, and pervasiveness of
cardiovascular disease, our highly accurate and accessible HART
blood tests are well-positioned to improve patient outcomes while
reducing costs.”
In addition to the HART CADhs test for diagnosing heart artery
obstruction, Prevencio offers a second multi-protein blood test,
HART CVE, which assesses one-year risk of a heart attack,
stroke or cardiovascular death. HART CADhs and HART CVE tests are
currently available to medical professionals for patient use. For
additional information, visit Prevencio, Inc.
About Prevencio HART Tests: Powered by AI, Prevencio is
revolutionizing blood tests for cardiovascular disease and custom
diagnostics for diagnostic, medical device and pharmaceutical
companies. Using this novel approach, the company has developed
seven blood tests that significantly improve diagnosis and risk
assessment for a variety of heart and blood vessel-related
complications.
For additional information, visit Prevencio.
HART test results have been peer-reviewed published 34
times, including at leading cardiovascular meetings—(European
Society of Cardiology Congress; American College of Cardiology
Scientific Sessions; American Heart Association Scientific
Sessions; American Diabetes Association Scientific Sessions;
Pediatric Academic Societies International Sessions; International
Spinal Cord Society Scientific Sessions; ASTRO Scientific Sessions;
Transcatheter Cardiovascular Therapeutics Sessions; American
Society of Clinical Oncology Genitourinary; and International
Kawasaki Disease Symposium) and in top-tier journals—(Journal of
American College of Cardiology; American Journal of Cardiology;
Clinical Cardiology; Open Heart; Biomarkers in Medicine; Journal of
American Heart Association; European Journal of Preventive
Cardiology; and International Journal of Cardiology).
About Prevencio, Inc.
Prevencio's value proposition is "Power of AI to Prevent the
Preventable” — That is, preventing unnecessary procedures, related
side effects, and expense, as well as improving patient outcomes
and clinical trials through more accurate blood tests for
cardiovascular disease & beyond. Prevencio utilizes Machine
Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers +
Proprietary Algorithms to deliver diagnostic & prognostic tests
that are significantly more accurate than standard-of-care stress
tests, genetic risk scores and coronary artery calcium. The company
is headquartered in Kirkland, Washington. For additional
information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein,
this press release contains forward-looking statements, such as
market need, acceptance, and size, the accuracy of which is
necessarily subject to various uncertainties of development-stage
companies. The company does not undertake to update disclosures
contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724949552/en/
Christiaan Boer, cboer@cplusc.com; 206-557-4309